Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02489695
Other study ID # AXIPAP
Secondary ID ET14-090
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2015
Est. completion date July 2019

Study information

Verified date September 2022
Source Centre Leon Berard
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, single arm, phase II study using a A'Hern single-stage procedure in patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) in first-line treatment.


Description:

Renal cell carcinoma (RCC) accounts for 2-3% of all adult malignancies worldwide, representing the seventh most common cancer in men and the ninth in women. The annual incidence is more than 337 000 cases and around 140 000 persons die every year. Half of patients with RCC are going to develop metastases, either with synchronous metastatic sites (25%) or during the follow up (25%). Papillary renal cell carcinoma (PRCC) represents 10-15% of RCC and is characterized by a cytogenetic profile distinct from other types of renal cancer. Histologically, PRCC could be separated in 2 distinct subtypes: type 1 and type 2. Vascular endothelial growth factor (VEGF) is a potent induction factor, playing a central role in angiogenesis and vascular permeability of tumor tissues. It binds to three specific receptors: VEGFR-1, VEGFR-2 and VEGFR-3, which are thus implicated in pathologic angiogenesis, tumor growth and metastatic progression of cancer. Patients with papillary histology demonstrated high expression of VEGF and VEGFR-2, making VEGF-targeted therapy an attractive therapeutic option. Recently, several studies have been developed to assess VEGF targeted therapy in patients with PRCC, mostly with sunitinib and with poor results (median progression-free survival (PFS) around 6 months). Axitinib is a potent, selective second-generation inhibitor of all three VEGF receptors. By inhibiting VEGF-mediated endothelial cell proliferation and survival, axitinib inhibits angiogenesis and tumor growth. In phase II trials, axitinib has shown anti-tumor activity with well-tolerated clinical safety profile in patients with advanced solid tumors, including RCC. Axitinib has been approved for the second-line treatment of advanced RCC on the basis of the pivotal randomized phase III AXIS trial results. 723 patients were enrolled and randomly assigned to receive axitinib or sorafenib. The median PFS assessed by independent review committee was 6.7 months with axitinib compared to 4.7 months with sorafenib (hazard ratio 0.665; 95% CI 0.544-0.812; one-sided p<0.0001). In all studies, the safety analysis showed a good tolerance of axitinib. The most common adverse reactions (occurring in >20% of treated subjects) were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia and hand-foot skin reaction. Dose discontinuations were reported in 4% of patients with axitinib vs. 8% with sorafenib. Little clinical data regarding the efficacy of recently developed VEGF targeted therapies in first-line treatment of PRCC is available. To date, there is no standard treatment, and evaluation of efficacy of the new targeted agents is clearly needed. The purpose of this study is to evaluate the efficacy and safety of axitinib in first-line treatment of patients with papillary renal cell carcinoma. Axitinib inhibits angiogenesis and vascular permeability in tumor tissues, leading to inhibition of tumor growth. Axitinib has shown antitumor activity in patients with RCC in phase II and III clinical trials. VEGF inhibitors are currently used in PRCC treatment, with disappointing results. Axitinib is more potent and selective against the VEGFR family compared with sorafenib and sunitinib in biochemical assays, and could have a similar efficacy with lesser toxicities, therefore may provide a clinical benefit in patients with PRCC.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date July 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Metastatic or locally advanced (inoperable) pure type 1 or 2 or mixed PRCC, histologically confirmed by central review: relevant slides [and blocks if available] with the initial histology report must be sent for central reading before confirmation of inclusion. 3. No prior systemic treatment for metastatic renal cancer (chemotherapy, immunotherapy, anti-angiogenic drugs, or treatment under evaluation). 4. At least one measurable site of disease as defined by RECIST 1.1 criteria. 5. ECOG performance status of 0, 1. 6. No toxicity > 1 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0) 7. In case of prior radiation therapy, discontinuation of irradiation for at least 4 weeks before first dose of study treatment. This period can be reduced to at least 1 week in case of radiotherapy in a limited field (< 10% of the whole body) while no side effects grade = 2 is expected and keeping at least one site for evaluation. 8. Adequate bone marrow, liver and renal function, as defined below: - Absolute neutrophil count = 1.5 G/L, platelet count = 100 G/L, and hemoglobin = 9 g/dL), - AST/ALT = 3 x upper limit of normal (ULN) (or = 5.0 x ULN if liver metastasis) and total bilirubin = 1.5 x ULN (= 2.5 x ULN if liver metastases), - Serum creatinine = 2.0 x ULN or creatinine clearance = 50 mL/min according to Cockroft formula or MDRD formula for patients older than 65 years, 9. Absence of proteinuria confirmed by urinary dipstick test. If the dipstick test is = 2+, proteinuria will be quantitated on a complete 24h urine sample (< 1 g/L of protein/24h sample). 10. Adequate contraceptive methods for fertile female subjects for the whole duration of the study and for 7 days after the last dose of study drug. Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study. 11. Covered by a medical insurance, in countries where applicable. 12. Written informed consent before any study specific procedures or assessments. Exclusion Criteria: 1. Prior TKI treatment in adjuvant situation for renal cancer. 2. Significant cardiovascular disease including: - Disorder of left ventricular function with a LVEF < 50%, - Uncontrolled arterial hypertension under adapted medication: systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg or both despite appropriate therapy, or patients under 3 antihypertensive therapies at screening, - Myocardial infarction, severe angina, or unstable angina within 6 months prior to inclusion, - History of serious ventricular arrhythmia (ie ventricular tachycardia or ventricular fibrillation), - Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication), - Coronary or peripheral artery bypass graft within 6 months of screening. 3. Presence of brain metastases on MRI or CT-scan performed within 28 days prior to inclusion. Patients with a history of brain metastases treated by surgery or stereotactic surgery, with normal brain MRI or CT-scan are allowed to participate. 4. Major surgical procedure, open biopsy, or serious none healing wound within 28 days prior to inclusion. 5. Any active acute or chronic or uncontrolled infection/disorder that impair the ability to evaluate the patient or the ability for the patient to complete the study. 6. Prior history of other malignancies other than PRCC (except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix) unless the subjects has been free of the disease for at least 3 years. 7. Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea. 8. Patient included in another clinical trial, except for supportive care trials. 9. Psychological, familial, sociological, or geographical conditions that would limit compliance with study protocol requirements. 10. Pregnant or breastfeeding women (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential).

Study Design


Intervention

Drug:
Axitinib
axitinib 10mg twice a day

Locations

Country Name City State
France ICO Paul Papin Angers
France Chu Bordeaux Bordeaux
France Centre Francois Baclesse Caen
France Centre Geogres François Leclerc Dijon
France Centre Leon Berard Lyon
France Institut Paoli Calmettes Marseille
France ICO - René Gauducheau Saint-herblain
France Institut Claudius Regaud Toulouse
France ICL Vandoeuvre-les-nancy
France Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

References & Publications (1)

Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B; GETUG collaborative group. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. Eur J Cancer. 2020 Apr;129:107-116. doi: 10.1016/j.ejca.2020.02.001. Epub 2020 Mar 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The efficacy of axitinib in first-line treatment of PRCC. 24-week progression-free rate 24-week
Secondary The safety of axitinib in patients with PRCC (NCI CTCAE v4) Week 2, 4, 8, 16 then Month 4, 6, 8,10, 12, 14, 16,18
Secondary The progression-free survival (RECIST 1.1) in each PRCC subtypes Week 2, 4, 8, 16 then Month 4, 6, 8,10, 12, 14, 16,18
Secondary The overall survival 43 month after first inclusion
Secondary The best response the best response recorded from the start of the treatment until disease progression Week 2, 4, 8, 16 then Month 4, 6, 8,10, 12, 14, 16,18
Secondary the objective response rate Week 2, 4, 8, 16 then Month 4, 6, 8,10, 12, 14, 16,18
Secondary the duration of response Week 2, 4, 8, 16 then Month 4, 6, 8,10, 12, 14, 16,18
See also
  Status Clinical Trial Phase
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT05043090 - Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC Phase 3
Terminated NCT00098618 - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Phase 2
Withdrawn NCT04603365 - Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Phase 2
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT04413123 - Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Phase 2
Completed NCT00126503 - Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Phase 1/Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Active, not recruiting NCT03541902 - Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Phase 2
Recruiting NCT03866382 - Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Phase 2
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Completed NCT00335556 - Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Phase 2
Recruiting NCT04981509 - Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Phase 2
Recruiting NCT04071223 - Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Phase 2
Recruiting NCT00898365 - Study of Kidney Tumors in Younger Patients
Recruiting NCT06339138 - Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Not yet recruiting NCT06146777 - Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy Phase 3
Active, not recruiting NCT03635892 - A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma Phase 2